Found: 32
Select item for more details and to access through your institution.
Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 4, p. 549, doi. 10.1007/s00280-024-04696-y
- By:
- Publication type:
- Article
Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 12, p. 1620, doi. 10.1002/jcph.1453
- By:
- Publication type:
- Article
Impact of reduced renal function on prognosis in Japanese patients with coronary artery disease: a prospective cohort of Shinken Database 2007.
- Published in:
- Hypertension Research, 2009, v. 32, n. 10, p. 920, doi. 10.1038/hr.2009.114
- By:
- Publication type:
- Article
Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.
- Published in:
- Journal of Human Genetics, 2009, v. 54, n. 1, p. 40, doi. 10.1038/jhg.2008.1
- By:
- Publication type:
- Article
Analysis of regulatory polymorphisms in organic ion transporter genes ( SLC22A) in the kidney.
- Published in:
- Journal of Human Genetics, 2008, v. 53, n. 7, p. 607, doi. 10.1007/s10038-008-0288-9
- By:
- Publication type:
- Article
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 2, p. 188, doi. 10.1002/cpt.3111
- By:
- Publication type:
- Article
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 530, doi. 10.1002/cpt.2986
- By:
- Publication type:
- Article
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 1, p. 81, doi. 10.1002/cpt.2561
- By:
- Publication type:
- Article
Treatment strategy and clinical outcome in Japanese patients with atrial fibrillation.
- Published in:
- Heart & Vessels, 2009, v. 24, n. 4, p. 287, doi. 10.1007/s00380-008-1121-2
- By:
- Publication type:
- Article
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 4, p. 307, doi. 10.1007/s00280-023-04612-w
- By:
- Publication type:
- Article
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 3, p. 369, doi. 10.1007/s00280-021-04292-4
- By:
- Publication type:
- Article
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 2, p. 307, doi. 10.1007/s00280-020-04121-0
- By:
- Publication type:
- Article
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2020, v. 86, n. 1, p. 87, doi. 10.1007/s00280-020-04102-3
- By:
- Publication type:
- Article
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Soft plaque detected on intravascular ultrasound is the strongest predictor of in-stent restenosis: an intravascular ultrasound study.
- Published in:
- European Heart Journal, 2004, v. 25, n. 22, p. 2026, doi. 10.1016/j.ehj.2004.07.039
- By:
- Publication type:
- Article
The potential of RF backscattered IVUS data and multidetector-row computed tomography images for tissue characterization of human coronary atherosclerotic plaques.
- Published in:
- International Journal of Cardiovascular Imaging, 2009, v. 25, n. 5, p. 471, doi. 10.1007/s10554-009-9446-1
- By:
- Publication type:
- Article
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 24, p. 4889, doi. 10.1002/cam4.4820
- By:
- Publication type:
- Article
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 366, doi. 10.1002/cpdd.850
- By:
- Publication type:
- Article
Use of Population Pharmacokinetic Analyses Among FDA‐Approved Biologics.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 914, doi. 10.1002/cpdd.658
- By:
- Publication type:
- Article
Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
- Published in:
- Clinical Pharmacokinetics, 2021, v. 60, n. 12, p. 1621, doi. 10.1007/s40262-021-01039-5
- By:
- Publication type:
- Article
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Multidrug Resistance-Associated Protein 2 (MRP2/ ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients.
- Published in:
- Clinical Pharmacokinetics, 2013, v. 52, n. 9, p. 751, doi. 10.1007/s40262-013-0069-2
- By:
- Publication type:
- Article